These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

84 related items for PubMed ID: 15598553

  • 1. Structure-based discovery of human L-xylulose reductase inhibitors from database screening and molecular docking.
    Carbone V, Ishikura S, Hara A, El-Kabbani O.
    Bioorg Med Chem; 2005 Jan 17; 13(2):301-12. PubMed ID: 15598553
    [Abstract] [Full Text] [Related]

  • 2. Crystal structure of human L-xylulose reductase holoenzyme: probing the role of Asn107 with site-directed mutagenesis.
    El-Kabbani O, Ishikura S, Darmanin C, Carbone V, Chung RP, Usami N, Hara A.
    Proteins; 2004 May 15; 55(3):724-32. PubMed ID: 15103634
    [Abstract] [Full Text] [Related]

  • 3. Structure of the tetrameric form of human L-Xylulose reductase: probing the inhibitor-binding site with molecular modeling and site-directed mutagenesis.
    El-Kabbani O, Carbone V, Darmanin C, Ishikura S, Hara A.
    Proteins; 2005 Aug 15; 60(3):424-32. PubMed ID: 15906319
    [Abstract] [Full Text] [Related]

  • 4. Structure-based design of inhibitors of human L-xylulose reductase modelled into the active site of the enzyme.
    Carbone V, Darmanin C, Ishikura S, Hara A, El-Kabbani O.
    Bioorg Med Chem Lett; 2003 Apr 17; 13(8):1469-74. PubMed ID: 12668014
    [Abstract] [Full Text] [Related]

  • 5. Importance of molecular computer modeling in anticancer drug development.
    Geromichalos GD.
    J BUON; 2007 Sep 17; 12 Suppl 1():S101-18. PubMed ID: 17935268
    [Abstract] [Full Text] [Related]

  • 6. An artificial intelligence approach to the study of the structural moieties relevant to drug-receptor interactions in aldose reductase inhibitors.
    Klopman G, Buyukbingol E.
    Mol Pharmacol; 1988 Dec 17; 34(6):852-62. PubMed ID: 3143909
    [Abstract] [Full Text] [Related]

  • 7. Discovery of small molecule inhibitors of integrin alphavbeta3 through structure-based virtual screening.
    Zhou Y, Peng H, Ji Q, Qi J, Zhu Z, Yang C.
    Bioorg Med Chem Lett; 2006 Nov 15; 16(22):5878-82. PubMed ID: 16982193
    [Abstract] [Full Text] [Related]

  • 8. Structure basis for the inhibitory mechanism of a novel DNase gamma-specific inhibitor, DR396.
    Sunaga S, Yoshimori A, Shiokawa D, Tanuma S.
    Bioorg Med Chem; 2006 Jun 15; 14(12):4217-26. PubMed ID: 16574417
    [Abstract] [Full Text] [Related]

  • 9. Virtual screening and scaffold hopping based on GRID molecular interaction fields.
    Ahlström MM, Ridderström M, Luthman K, Zamora I.
    J Chem Inf Model; 2005 Jun 15; 45(5):1313-23. PubMed ID: 16180908
    [Abstract] [Full Text] [Related]

  • 10. Mining the NCI antiviral compounds for HIV-1 integrase inhibitors.
    Deng J, Kelley JA, Barchi JJ, Sanchez T, Dayam R, Pommier Y, Neamati N.
    Bioorg Med Chem; 2006 Jun 01; 14(11):3785-92. PubMed ID: 16460953
    [Abstract] [Full Text] [Related]

  • 11. Automatic and efficient decomposition of two-dimensional structures of small molecules for fragment-based high-throughput docking.
    Kolb P, Caflisch A.
    J Med Chem; 2006 Dec 14; 49(25):7384-92. PubMed ID: 17149868
    [Abstract] [Full Text] [Related]

  • 12. Protein structure-based de novo design and synthesis of aldose reductase inhibitors.
    Iwata Y, Naito S, Itai A, Miyamoto S.
    Drug Des Discov; 2001 Dec 14; 17(4):349-59. PubMed ID: 11765138
    [Abstract] [Full Text] [Related]

  • 13. Diketo acid pharmacophore. 2. Discovery of structurally diverse inhibitors of HIV-1 integrase.
    Dayam R, Sanchez T, Neamati N.
    J Med Chem; 2005 Dec 15; 48(25):8009-15. PubMed ID: 16335925
    [Abstract] [Full Text] [Related]

  • 14. Human sialidase inhibitors: design, synthesis, and biological evaluation of 4-acetamido-5-acylamido-2-fluoro benzoic acids.
    Magesh S, Savita V, Moriya S, Suzuki T, Miyagi T, Ishida H, Kiso M.
    Bioorg Med Chem; 2009 Jul 01; 17(13):4595-603. PubMed ID: 19450982
    [Abstract] [Full Text] [Related]

  • 15. Identification of some novel AHAS inhibitors via molecular docking and virtual screening approach.
    Wang JG, Xiao YJ, Li YH, Ma Y, Li ZM.
    Bioorg Med Chem; 2007 Jan 01; 15(1):374-80. PubMed ID: 17049866
    [Abstract] [Full Text] [Related]

  • 16. N-(thiazol-2-yl)-2-thiophene carboxamide derivatives as Abl inhibitors identified by a pharmacophore-based database screening of commercially available compounds.
    Manetti F, Falchi F, Crespan E, Schenone S, Maga G, Botta M.
    Bioorg Med Chem Lett; 2008 Aug 01; 18(15):4328-31. PubMed ID: 18621522
    [Abstract] [Full Text] [Related]

  • 17. Synthesis and docking studies of new 1,4-dihydropyridines containing 4-(5)-Chloro-2-ethyl-5-(4)-imidazolyl substituent as novel calcium channel agonist.
    Davood A, Nematollahi AR, Iman M, Shafiee A.
    Arch Pharm Res; 2009 Apr 01; 32(4):481-7. PubMed ID: 19407963
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Quantitative evaluation of each catalytic subsite of cathepsin B for inhibitory activity based on inhibitory activity-binding mode relationship of epoxysuccinyl inhibitors by X-ray crystal structure analyses of complexes.
    Watanabe D, Yamamoto A, Tomoo K, Matsumoto K, Murata M, Kitamura K, Ishida T.
    J Mol Biol; 2006 Oct 06; 362(5):979-93. PubMed ID: 16950396
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.